Increased number of [125I] BH-substance P receptors in schizophrenia

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 22, Issue 8, 1998, Pages 1295-1299

  Rioux, Lise ^a,d   Nissanov, Jonathan ^b   Joyce, Jeffrey N ^a,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b DREXEL UNIVERSITY   (United States)

^c SUN HEALTH RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

NK1 receptors; Striatum; Tachykinin

Indexed keywords

BOLTON HUNTER REAGENT I 125; NEUROKININ 1 RECEPTOR; SUBSTANCE P; SUBSTANCE P RECEPTOR;

ADULT; AGED; ARTICLE; AUTORADIOGRAPHY; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; HUMAN; HUMAN TISSUE; NUCLEUS ACCUMBENS; RECEPTOR DENSITY; SCHIZOPHRENIA;

EID: 0032211899     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-5846(98)00084-0     Document Type: Article

References (17)

1. AMERICAIN PSYCHIATRIC ASSOCIATION (1987): Diagnostic and statistical manual of mental disorders, 3rd ed rev., 567 p, American Psychiatric Press, Washington DC.
2. ARNOLD, S.E., GUR, R.E., SHAPIRO, R.M., FISHER, K.R., MOBERG, P.J., GIBNEY, M.R., GUR, R.C., BLACKWELL, P. and TROJANOVSKI, J.Q. (1995): Perspective clinicopathologic studies of schizophrenia: accrual and assessment of patients. Am. J. Psychiatry, 152: 731-737.
3. BANNON M.J., ELLIOTT P.J. and BUNNEY E.B. (1987): Striatal tachykinin biosynthesis: regulation of mRNA and peptide levels by dopamine agonists and antagonists. Mol. Brain Res., 3: 31-37.
4. CLEVENS R.A. and BEAL M.F. (1989): Substance P-like immunoreactivity in brains with pathological features of Parkinson's and Alzheimer's diseases. Brain Res., 486: 398-390.
5. CREESE I., BURT D.R. and SNYDER S.H. (1976): Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science, 192 (4238): 481-483.
6. CRUZ C.J. and BECKSTEAD R.M. (1989): Nigrostriatal dopamine neurons are required to maintain basal levels of substance P in the rat substantia nigra. Neuroscience. 30(2): 331-338.
7. DAVIDSON M., KEEFE R.S., MOHS R.C., SIEVER L.J., LOSONCZY M.F., HORVATH T.B. and DAVIS K.L. (1987): L-dopa challenge and relapse in schizophrenia. Am J Psychiatry, 144(7): 934-938.
8. DIETL M., SANCHEZ M., PROBST A. and PALACIOS M. (1989): Substance P receptors in the human spinal cord: decrease in amyotrophic lateral sclerosis. Brain Res., 483: 39-49.
9. HAVERSTICK D.M., RUBENSTEIN A. and BANNON M.J. (1989): Striatal tachykinin gene expression regulated by interaction of D-1 and D-2 receptors. J. Pharmacol. Exp. Ther., 248: 858-862.
10. MAUBORGNE A., JANOY-AGID F., LEGRAND J.C., AGID Y. and CESSELIN F. (1983): Decrease of substance P-like immunoreactivity in the substantia nigra and pallidum of parkinsonian brains. Brain Res, 268: 167-170.
11. MURRAY A.M., WEIHMUELLER F.B., MARSHALL J.F., HURTIG H.I., GOTTLEIB G.L. and JOYCE J.N. (1995): Damage to dopamine systems differs between Parkinson's-disease and Alzheimer's-disease with parkinsonism. Annals Neurol., 37(3): 300-312.
12. RIOUX L. and JOYCE J.N. (1993): NK1 receptors are differentially affected in Parkinson's and Alzheimer's Disease. J. Neural Trans., 6: 199-210.
13. SONSALLA P.K., GIBB J.W. and HANSON G.R. (1984): Opposite responses in the striato-nigral substance P system to D1 and D2 receptor activation. Eur. J. Pharmacol., 105:185-187.
14. SEEMAN P., LEE T., CHAU-WONG M. and WONG K. (1976): Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature, 261 (5562): 717-719.
15. TENOVNO O., RUNNE V.K. and VILJANEN M.K. (1984): Substance-P immunoreactivity in the postmortem parkinsonian brain. Brain Res., 303: 113-116.
16. TORU M., WATANABA S., SHIBUYA H., NISHIKAWA T., NODA K., MITSUSHIO H., ICHIKAWA H., KORUMAJI A., TAKASHIMA M., MATAGA N. and OGAWA A. (1988): Neurotransmitters, receptors and neuropeptides in post-mortem brains of chronic schizophrenic patients. Acta psychiatr. Scand., 78: 121-137.
17. YOUNG W.S., BONNER T.I. and BRANN M.R. (1986): Mesencephalic dopamine neurons regulate the expression of neuropeptide mRNAs in the rat forebrain. Proc Natl Acad Sci USA, 83: 9827-9831.